Literature DB >> 14253244

THE EMERGENCE OF ISONIAZID-RESISTANT CULTURES IN PATIENTS WITH PULMONARY TUBERCULOSIS DURING TREATMENT WITH ISONIAZID ALONE OR ISONIAZID PLUS PAS.

J B SELKON, S DEVADATTA, K G KULKARNI, D A MITCHISON, A S NARAYANA, C N NAIR, K RAMACHANDRAN.   

Abstract

Previous reports from the Tuberculosis Chemotherapy Centre, Madras, have described a comparison of four regimens (three of isoniazid alone and one of isoniazid plus PAS) in the treatment of pulmonary tuberculosis and an investigation of the serum isoniazid levels in the patients concerned. The present report studies the emergence of isoniazid-resistant organisms in these patients during treatment. All patients with an unsatisfactory response to treatment yielded resistant cultures, showing that the isoniazid dosage was never too low to inhibit sensitive organisms. From the degree of resistance of the first resistant cultures and of the six-month cultures from the patients treated with isoniazid alone it was concluded that resistance emerged in two stages. In the first stage, very earlyin treatment, highly resistant mutant bacilli grew freely whatever the isoniazid dosage, but mutants of lower resistance were prevented from growing to an extent dependent on the peak isoniazid concentration in the serum. Consequently, when the isoniazid dosage was increased the proportion of patients with resistant organisms decreased, since fewer low-resistance strains were able to develop. In the second stage, organisms with relatively low resistance continued to multiply, though still partially inhibited by isoniazid, and became more resistant, particularly in slow inactivators. The first-stage events determined the results of treatment since, once resistance had emerged, its extent was unrelated to the patient's eventual progress. These findings emphasize the importance of early intensive chemotherapy and adjustment of the isoniazid dosage according to peak serum concentrations rather than concentrations measured three or six hours after the dose. Concomitant administration of PAS prevented emergence of isoniazid resistance in many patients and in others delayed its emergence and reduced its degree, possibly because growth in the second stage was slow.

Entities:  

Keywords:  AMINOSALICYLIC ACID; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY; EXPERIMENTAL LAB STUDY; ISONIAZID; MYCOBACTERIUM; TUBERCULOSIS, PULMONARY

Mesh:

Substances:

Year:  1964        PMID: 14253244      PMCID: PMC2555166     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  10 in total

1.  Progress in the second year of patients with quiescent pulmonary tuberculosis after a year of domiciliary chemotherapy, and influence of further chemotherapy on the relapse rate.

Authors:  S VELU; R H ANDREWS; J H ANGEL; S DEVADATTA; W FOX; P R GANGADHARAM; A S NARAYANA; C V RAMAKRISHNAN; J B SELKON; P R SOMASUNDARAM
Journal:  Bull World Health Organ       Date:  1961       Impact factor: 9.408

2.  The uptake of isoniazid by mycobacteria and its relation to isoniazid susceptibility.

Authors:  M TSUKAMURA; S TSUKAMURA; E NAKANO
Journal:  Am Rev Respir Dis       Date:  1963-02

3.  The uptake of isoniazid by washed cell suspensions of Mycobacteria and other organisms.

Authors:  J YOUATT
Journal:  Aust J Exp Biol Med Sci       Date:  1958-06

4.  [Percentage of isoniazid-resistant and streptomycin-resistant variants in wild strains of Mycobacterium tuberculosis on Loewenstein-Jensen medium].

Authors:  G CANETTI; J GROSSET
Journal:  Ann Inst Pasteur (Paris)       Date:  1961-07

5.  The clinical significance of positive cultures and of isoniazid-resistant tubercle bacilli during the treatment of pulmonary tuberculosis; report to the Tuberculosis Chemotherapy Trials Committee of the Medical Research Council.

Authors:  W FOX; I SUTHERLAND
Journal:  Thorax       Date:  1955-06       Impact factor: 9.139

6.  Mode of action of isoniazid. II.

Authors:  W R BARCLAY; D KOCH-WESER; R H EBERT
Journal:  Am Rev Tuberc       Date:  1954-11

7.  Sterilization of tubercle bacilli by isonicotinic acid hydrazide and the incidence of variants resistant to the drug in vitro.

Authors:  G MIDDLEBROOK
Journal:  Am Rev Tuberc       Date:  1952-06

8.  Rate of inactivation of isoniazid in South Indian patients with pulmonary tuberculosis.

Authors:  P R GANGADHARAM; A L BHATIA; S RADHAKRISHNA; J B SELKON
Journal:  Bull World Health Organ       Date:  1961       Impact factor: 9.408

9.  Rate of inactivation of isoniazid in South Indian patients with pulmonary tuberculosis. 3. Serum concentrations of isoniazid produced by three regimens of isoniazid alone and one of isoniazid plus PAS.

Authors:  P R GANGADHARAM; S DEVADATTA; W FOX; C N NAIR; J B SELKON
Journal:  Bull World Health Organ       Date:  1961       Impact factor: 9.408

10.  Rate of inactivation of isoniazid in South Indian patients with pulmonary tuberculosis. 2. Clinical implications in the treatment of pulmonary tuberculosis with isoniazid either alone or in combination with PAS.

Authors:  J B SELKON; W FOX; P R GANGADHARAM; K RAMACHANDRAN; C V RAMAKRISHNAN; S VELU
Journal:  Bull World Health Organ       Date:  1961       Impact factor: 9.408

  10 in total
  22 in total

1.  CHEMOTHERAPY OF TUBERCULOSIS: A BACTERIOLOGIST'S VIEWPOINT.

Authors:  D A MITCHISON
Journal:  Br Med J       Date:  1965-05-22

2.  The combination of meropenem and levofloxacin is synergistic with respect to both Pseudomonas aeruginosa kill rate and resistance suppression.

Authors:  Arnold Louie; Caroline Grasso; Nadzeya Bahniuk; Brian Van Scoy; David L Brown; Robert Kulawy; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2010-04-05       Impact factor: 5.191

Review 3.  Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 2.

Authors:  G L Drusano; William Hope; Alasdair MacGowan; Arnold Louie
Journal:  Antimicrob Agents Chemother       Date:  2015-12-28       Impact factor: 5.191

4.  Recent advances in tuberculosis: New drugs and treatment regimens.

Authors:  Derek J Sloan; Geraint R Davies; Saye H Khoo
Journal:  Curr Respir Med Rev       Date:  2013-06-01

5.  Impact of antimicrobial dosing regimen on evolution of drug resistance in vivo: fluconazole and Candida albicans.

Authors:  D Andes; A Forrest; A Lepak; J Nett; K Marchillo; L Lincoln
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

6.  In vivo fluconazole pharmacodynamics and resistance development in a previously susceptible Candida albicans population examined by microbiologic and transcriptional profiling.

Authors:  D Andes; A Lepak; J Nett; L Lincoln; K Marchillo
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

7.  The population dynamics of antimicrobial chemotherapy.

Authors:  M Lipsitch; B R Levin
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

8.  Thioridazine pharmacokinetic-pharmacodynamic parameters "Wobble" during treatment of tuberculosis: a theoretical basis for shorter-duration curative monotherapy with congeners.

Authors:  Sandirai Musuka; Shashikant Srivastava; Chandima Wasana Siyambalapitiyage Dona; Claudia Meek; Richard Leff; Jotam Pasipanodya; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191

9.  The combination of rifampin plus moxifloxacin is synergistic for suppression of resistance but antagonistic for cell kill of Mycobacterium tuberculosis as determined in a hollow-fiber infection model.

Authors:  G L Drusano; Nicole Sgambati; Adam Eichas; David L Brown; Robert Kulawy; Arnold Louie
Journal:  MBio       Date:  2010-08-10       Impact factor: 7.867

Review 10.  Treatment of active pulmonary tuberculosis in adults: current standards and recent advances. Insights from the Society of Infectious Diseases Pharmacists.

Authors:  Ronald G Hall; Richard D Leff; Tawanda Gumbo
Journal:  Pharmacotherapy       Date:  2009-12       Impact factor: 4.705

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.